Form 4: Replimune Group Director Acquires Stock Options
SEC Form 4
Christy J. Oliger, a director of Replimune Group, Inc., acquired stock options for 32,000 shares on April 1, 2024.
Summary
- This is a Form 4 filing indicating a change in beneficial ownership for Christy J. Oliger, a director of Replimune Group, Inc.
- On April 1, 2024, Oliger acquired stock options for 32,000 shares of Replimune's common stock at an exercise price of $7.73.
- These options vest entirely on April 1, 2025, and expire on April 1, 2034.
- Following the transaction, Oliger directly owns options for 32,000 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which can be interpreted as a positive sign but doesn't provide substantial information about the company's overall performance.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers.
Stakeholder Impact
- Shareholders may view the director's stock option acquisition as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of transaction: Christy J. Oliger acquired stock options. |
| 04/01/2025 | Vesting date: The stock options vest entirely. |
| 04/01/2034 | Expiration date: The stock options expire. |
| 04/03/2024 | Date of filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.